Morgan Stanley Adicet Bio, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 72,226 shares of ACET stock, worth $71,503. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,226

Previous 1,683 4191.5%

Holding current value

$71,503

Previous $1,000 4300.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$0.45 - $0.82 $31,744 - $57,845	70,543 Added 4191.5%	72,226 $44,000
Q1 2025 May 15, 2025	SELL	$0.76 - $1.09 $4,743 - $6,803	-6,242 Reduced 78.76%	1,683 $1,000
Q4 2024 Feb 14, 2025	SELL	$0.86 - $1.52 $224,446 - $396,695	-260,984 Reduced 97.05%	7,925 $7,000
Q3 2024 May 14, 2025	SELL	$1.07 - $1.63 $907,462 - $1.38 Million	-848,096 Reduced 75.93%	268,909 $387,000
Q3 2024 Nov 14, 2024	SELL	$1.07 - $1.63 $907,462 - $1.38 Million	-848,096 Reduced 75.93%	268,909 $387,000
Q2 2024 May 14, 2025	BUY	$1.21 - $2.4 $1.34 Million - $2.66 Million	1,109,080 Added 13994.7%	1,117,005 $1.35 Million
Q2 2024 Oct 17, 2024	SELL	$1.21 - $2.4 $3.57 Million - $7.08 Million	-2,950,300 Reduced 72.54%	1,117,005 $1.35 Million
Q2 2024 Aug 14, 2024	SELL	$1.21 - $2.4 $3.57 Million - $7.08 Million	-2,950,300 Reduced 72.54%	1,117,005 $1.35 Million
Q1 2024 Oct 17, 2024	BUY	$1.76 - $3.45 $5.19 Million - $10.2 Million	2,950,300 Added 264.13%	4,067,305 $9.56 Million
Q1 2024 Aug 16, 2024	BUY	$1.76 - $3.45 $2.23 Million - $4.38 Million	1,268,496 Added 45.32%	4,067,305 $9.56 Million
Q1 2024 May 15, 2024	BUY	$1.76 - $3.45 $2.23 Million - $4.38 Million	1,268,496 Added 45.32%	4,067,305 $9.56 Million
Q4 2023 Aug 16, 2024	BUY	$1.11 - $1.89 $1.87 Million - $3.18 Million	1,681,804 Added 150.56%	2,798,809 $5.29 Million
Q4 2023 Feb 13, 2024	SELL	$1.11 - $1.89 $1.15 Million - $1.96 Million	-1,037,568 Reduced 27.05%	2,798,809 $5.29 Million
Q3 2023 Nov 15, 2023	BUY	$1.37 - $3.4 $1.9 Million - $4.72 Million	1,388,534 Added 56.72%	3,836,377 $5.26 Million
Q2 2023 Aug 14, 2023	BUY	$2.13 - $7.13 $1.72 Million - $5.76 Million	807,965 Added 49.27%	2,447,843 $5.95 Million
Q1 2023 May 15, 2023	BUY	$5.52 - $9.23 $43,188 - $72,215	7,824 Added 0.48%	1,639,878 $9.45 Million
Q4 2022 Feb 14, 2023	SELL	$7.72 - $21.27 $220,969 - $608,811	-28,623 Reduced 1.72%	1,632,054 $14.6 Million
Q3 2022 Nov 14, 2022	BUY	$13.43 - $18.74 $361,804 - $504,855	26,940 Added 1.65%	1,660,677 $23.6 Million
Q2 2022 Oct 27, 2022	BUY	$10.26 - $20.81 $16.6 Million - $33.7 Million	1,618,781 Added 10823.62%	1,633,737 $23.9 Million
Q2 2022 Aug 15, 2022	BUY	$10.26 - $20.81 $16.6 Million - $33.7 Million	1,618,781 Added 10823.62%	1,633,737 $23.9 Million
Q1 2022 Oct 27, 2022	SELL	$11.53 - $19.97 $18.7 Million - $32.3 Million	-1,618,781 Reduced 99.08%	14,956 $299,000
Q1 2022 May 13, 2022	BUY	$11.53 - $19.97 $7,160 - $12,401	621 Added 4.33%	14,956 $299,000
Q4 2021 Feb 14, 2022	SELL	$7.37 - $17.49 $9,160 - $21,740	-1,243 Reduced 7.98%	14,335 $250,000
Q3 2021 Nov 15, 2021	BUY	$6.29 - $9.93 $97,985 - $154,689	15,578 New	15,578 $123,000

Others Institutions Holding ACET

# of Institutions

Shares Held

53.1M

Call Options Held

27.2K

Put Options Held

View Full List

About Adicet Bio, Inc.

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $39.6M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

More about ACET

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account